Description

Health Canada reviewed the potential risk of acute kidney injury with the use of levetiracetam, because of an article that was published by the WHO suggesting this risk. Health Canada assessed the risk of acute kidney injury, which is defined as a sudden loss of kidney function, including kidney failure and interstitial nephritis. Interstitial nephritis is the inflammation of the kidneys and is one of the conditions that may lead to kidney failure.

Resources

Name	Format	Description	Link
Summary Safety Review - KEPPRA (levetiracetam) - Assessing the Potential Risk of Acute Kidney Injury (Acute renal failure/Interstitial nephritis)	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-keppra-levetiracetam-assessing-potential-risk-kidney-injury-renal-failure.html
Summary Safety Review - KEPPRA (levetiracetam) - Assessing the Potential Risk of Acute Kidney Injury (Acute renal failure/Interstitial nephritis)	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/examens-innocuite/resume-examen-innocuite-keppra-levetiracetam-evaluation-risque-potentiel-aigues-insuffisance-renale.html

Tags

Topics

Categories